

Special Issue

Immune Mechanisms in Dermatology

Message from the Guest Editor

We develop local therapies based on Toll-like receptor (TLR) modulators, as these factors of innate immunity are well-understood in the signaling cascade from cutaneous viral infections (including DNA) to skin carcinomas. We correlate the presence of basal cell carcinoma with decreased immunity of the individual as we assess the signaling function of the skin. We understand the superior acantholysis and apoptolysis in pemphigus and are more confident in the diagnosis when we corroborate histopathological examination with DIF and IIF. We treat urticaria with biologicals against IgE and psoriasis with biologicals against activated interleukins. We use PRP therapy in various conditions with promising results. The aim of this issue of the prestigious journal *Biomedicines* is to publish quality research that pushes forward the field of knowledge in dermatological immunology.

Guest Editor

Dr. Olga Simionescu

Chief of the First Clinic of Dermatology, Department of Dermatology, "Carol Davila" University of Medicine and Pharmacy, Colentina Hospital, 020125 Bucharest, Romania

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/199487

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).